Table Info

Table 3.

Pros and cons of CSII and CGM technology among subjects with T2D

	*Pros*	*Cons*
Both for CSII and CGM	Improvement of HbA1c level in short and long-term	Only for selected patients suitable for technology Necessity of time for specific training Need for healthcare provider team trained to technology use
	Usually discrete and easy to wear Improved quality of life Useful and effective in case of pregnancy and its planning	Risk of skin reactions at the insertion site Risk of non-adherence or early discontinuation of technology use
		Short term* cost and its coverage
CGM specific issues	Reduction of hypoglycemic events Complete glucose profiles No calibration needed for some devices	Risk of long term burn-out by alarms Big amount of data to be interpreted Calibration needed for some devices
CSII specific issues	Tailored insulin therapy Efficacy both in obese and in non-obese patients

long term cost must be evaluated in cost effectiveness studies, to evaluate if long term reduction of diabetes related complications could compensate initial costs

Declarations

Author contributions

AMB and AL conceived the idea of the manuscript and designed the project; AA, AC, AMB and EP organized the collected data to review; EP wrote the first draft of the manuscript with the supervision of AMB, AC and AL; AC, AMB and AL contributed to work design and critically reviewed the manuscript. All authors discussed the project, contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26:2598–603. [DOI] [PubMed]

Bosi E, Scavini M, Ceriello A, Cucinotta D, Tiengo A, Marino R, et al. Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial. Diabetes Care. 2013;36:2887–94. [DOI] [PubMed] [PMC]

Rodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther. 2017;19 Suppl 3:S25–37. [DOI] [PubMed] [PMC]

Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254–63. [DOI] [PubMed]

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203. [DOI] [PubMed] [PMC]

Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001;161:1653–9. [DOI] [PubMed]

Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al.; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–47. [DOI] [PubMed]

Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010:CD005103. [DOI] [PubMed]

Scott ES, McGrath RT, Januszewski AS, Calandro D, Hardikar AA, O’Neal DN, et al. HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment. BMJ Open. 2019;9:e033059. [DOI]

10.

Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25:765–74. [DOI] [PubMed]

11.

Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324:705. [DOI] [PubMed] [PMC]

12.

EQuality1 Study Group--Evaluation of QUALITY of Life and Costs in Diabetes Type 1; Nicolucci A, Maione A, Franciosi M, Amoretti R, Busetto E, Capani F, et al. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med. 2008;25:213–20. [DOI] [PubMed]

13.

Bode BW. Insulin pump use in type 2 diabetes. Diabetes Technol Ther. 2010;12 Suppl 1:S17–21. [DOI] [PubMed] [PMC]

14.

Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Javier Castaneda, et al.; OpT2mise Study Group. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet. 2014;384:1265–72. [DOI] [PubMed]

15.

Aronson R, Reznik Y, Conget I, Castañeda JA, Runzis S, Lee SW, et al.; OpT2mise Study Group. Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial. Diabetes Obes Metab. 2016;18:500–7. [DOI] [PubMed] [PMC]

16.

Pickup JC, Reznik Y, Sutton AJ. Glycemic control during continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: individual patient data meta-analysis and meta-regression of randomized controlled trials. Diabetes Care. 2017;40:715–22. [DOI] [PubMed]

17.

Milluzzo A, Vigneri P, Martorana F, Vigneri R, Sciacca L. Type 2 diabetes and cancer: problems and suggestions for best patient management. Explor Med. 2020;1:184–204.

18.

Berthe E, Lireux B, Coffin C, Goulet-Salmon B, Houlbert D., Boutreux S, et al. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res. 2007;39:224–9. [DOI] [PubMed]

19.

American Diabetes Association. Standards of medical care in diabetes--2009. Diabetes Care. 2009;32 Suppl 1:S13–61. [DOI] [PubMed] [PMC]

20.

National coverage analysis (NCA) tracking sheet for insulin pump: C-peptide levels as a criterion for use (CAG-00092R) [Internet]. Maryland: the U.S. Centers for Medicare & Medicaid Services; 2004 [cited 2020 Sep 14]. Available from: https://www.cms.gov/medicare-coverage-database/details/nca-tracking-sheet.aspx?NCAId=109&fromdb=true

21.

Ginsberg BH. Patch pumps for insulin. J Diabetes Sci Technol. 2019;13:27–33. [DOI] [PubMed] [PMC]

22.

Lajara R, Davidson JA, Nikkel CC, Morris TL. Clinical and cost-effectiveness of insulin delivery with V-GO (®) disposable insulin delivery device versus multiple daily injections in patients with type 2 diabetes inadequately controlled on basal insulin. Endocr Pract. 2016;22:726–35. [DOI] [PubMed]

23.

Wahlqvist P, Warner J, Morlock R. Cost-effectiveness of simple insulin infusion devices compared to multiple daily injections in uncontrolled type 2 diabetics in the United States based on a simulation model. J Health Econ Outcomes Res. 2018;6:84–95. [DOI] [PubMed] [PMC]

24.

Vigersky RA, Huang S, Cordero TL, Shin J, Lee SW, Chhabra H, et al.; OpT2mise Study Group. Improved HbA1c, total daily insulin dose, and treatment satisfaction with insulin pump therapy compared to multiple daily insulin injections in patients with type 2 diabetes irrespective of baseline C-peptide levels. Endocr Pract. 2018;24:446–52. [DOI] [PubMed]

25.

Dicembrini I, Mannucci E, Monami M, Pala L. Impact of technology on glycemic control in type 2 diabetes: a meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion. Diabetes Obes Metab. 2019;21:2619–25. [DOI] [PubMed]

26.

Ida S, Kaneko R, Murata K. Utility of real-time and retrospective continuous glucose monitoring in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J Diabetes Res. 2019;2019:4684815. [DOI] [PubMed] [PMC]

27.

Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al.; DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317:371–8. [DOI] [PubMed]

28.

Carlson AL, Mullen DM, Bergenstal RM. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. Diabetes Technol Ther. 2017;19:S4–11. [DOI] [PubMed] [PMC]

29.

Vigersky RA, Fonda SJ, Chelleppa M, Walker MS, Ehrhardt NM. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care. 2012;35:32–8. [DOI] [PubMed] [PMC]

30.

Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, et al.; DIAMOND Study Group. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167:365–74. [DOI] [PubMed]

31.

Allen NA, Fain JA, Braun B, Chipkin SR. Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: a randomized clinical trial. Diabetes Res Clin Pract. 2008;80:371–9. [DOI] [PubMed] [PMC]

32.

Fonda SJ, Graham C, Munakata J, Powers JM, Price D, Vigersky RA. The cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes. J Diabetes Sci Technol. 2016;10:898–904. [DOI] [PubMed] [PMC]

33.

American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes--2020. Diabetes Care. 2020;43:S77–88. [DOI] [PubMed]

34.

New JP, Ajjan R, Pfeiffer AFH, Freckmann G. Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS). Diabet Med. 2015;32:609–17. [DOI] [PubMed]

35.

Wright AD, Cull CA, Macleod KM, Holman RR; UKPDS Group. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications. 2006;20:395–401. [DOI] [PubMed]

36.

Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al.; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410–8. [DOI] [PubMed]

37.

Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in type 2 diabetes--more common than you think: a continuous glucose monitoring study. J Diabetes Sci Technol. 2015;9:999–1005. [DOI] [PubMed] [PMC]

38.

Zick R, Petersen B, Richter M, Haug C; SAFIR Study Group. Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with Type 2 diabetes on multiple daily insulin injection therapy. Diabetes Technol Ther. 2007;9:483–92. [DOI] [PubMed]

39.

Pazos-Couselo M, Garcí a-López JM, González-Rodrí guez M, Gude F, Mayán-Santos JM, Rodrí guez-Segade S, et al. High incidence of hypoglycemia in stable insulin-treated type 2 diabetes mellitus: continuous glucose monitoring vs. self-monitored blood glucose. Observational prospective study. Can J Diabetes. 2015;39:428–33. [DOI] [PubMed]

40.

Mantovani A, Beatrice G, Petracca G, Pampagnin F, Sandri D, Targher G. GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis. Explor Med. 2020;1:108–23.

41.

FLAT-SUGAR trial investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care. 2016;39:973–81. [DOI] [PubMed]

42.

Taylor PJ, Thompson CH, Luscombe-Marsh ND, Wycherley TP, Wittert G, Brinkworth GD, et al. Tolerability and acceptability of real-time continuous glucose monitoring and its impact on diabetes management behaviors in individuals with Type 2 Diabetes - a pilot Study. Diabetes Res Clin Pract. 2019;155:107814. [DOI] [PubMed]

43.

Ruedy KJ, Parkin CG, Riddlesworth TD, Graham C; DIAMOND Study Group. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11:1138–46. [DOI] [PubMed] [PMC]

44.

Polonsky WH, Fisher L, Hessler D, Edelman SV. Development of a new measure for assessing glucose monitoring device-related treatment satisfaction and quality of life. Diabetes Technol Ther. 2015;17:657–63. [DOI] [PubMed]

45.

Bergenstal RM, Ahmann AJ, Bailey T, Beck RW, Bissen J, Buckingham B, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile (AGP). Diabetes Technol Ther. 2013;15:198–211. [DOI] [PubMed]

46.

Bailey TS, Grunberger G, Bode BW, Handelsman Y, Hirsch IB, Jovanovič L, et al.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE). American Association of Clinical Endocrinologists and American College of Endocrinology 2016 outpatient glucose monitoring consensus statement. Endocr Pract. 2016;22:231–61. [DOI] [PubMed]

47.

Zheng M, Luo Y, Lin W, Khoja A, He Q, Yang S, et al. Comparing effects of continuous glucose monitoring systems (CGMs) and self-monitoring of blood glucose (SMBG) amongst adults with type 2 diabetes mellitus: a systematic review protocol. Syst Rev. 2020;9:120. [DOI] [PubMed] [PMC]

48.

Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, et al. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96:2968–79. [DOI] [PubMed]

49.

Janapala RN, Jayaraj JS, Fathima N, Kashif T, Usman N, Dasari A, et al. Continuous glucose monitoring versus self-monitoring of blood glucose in type 2 diabetes mellitus: a systematic review with meta-analysis. Cureus. 2019;11:e5634. [DOI] [PubMed] [PMC]

50.

Shivers JP, Mackowiak L, Anhalt H, Zisser H. “Turn it off!”: diabetes device alarm fatigue considerations for the present and the future. J Diabetes Sci Technol. 2013;7:789–94. [DOI] [PubMed] [PMC]

51.

Bilir SP, Hellmund R, Wehler E, Li H, Munakata J, Lamotte M. The cost-effectiveness of a flash glucose monitoring system for management of patients with type 2 diabetes receiving intensive insulin treatment in Sweden. Eur endocrinol. 2018;14:80–5. [DOI] [PubMed] [PMC]

52.

Dunn TC, Xu Y, Hayter G, Ajjan RA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2018;137:37–46. [DOI] [PubMed]

53.

Laurenzi A, Caretto A, Barrasso M, Bolla AM, Dozio N, Molinari C, et al. Frequency of flash glucose monitoring readings, hemoglobin A1c and time in range: a real life study in adults with type 1 diabetes. Acta Diabetol. 2020;57:1395–7. [DOI] [PubMed]

54.

Yaron M, Roitman E, Aharon-Hananel G, Landau Z, Ganz T, Karp M, et al. Intervention of the flash glucose sensing technology on glycemic control and treatment satisfaction in patients with type 2 diabetes treated intensively using insulin--a randomized controlled trial. Diabetes. 2018;67:908-P. [DOI]

55.

Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55–73. [DOI] [PubMed] [PMC]

56.

Midyett K, Unger JR, Wright EE, Daniel TD, Kruger DF, Henry RR, et al. A pilot study to assess clinical utility and user experience of professional continuous glucose monitoring among people with type 2 diabetes. Clin Diabetes. 2019;37:57–64. [DOI] [PubMed] [PMC]

57.

Anjana RM, Kesavadev J, Neeta D, Tiwaskar M, Pradeepa R, Jebarani S, et al. A multicenter real-life study on the effect of flash glucose monitoring on glycemic control in patients with type 1 and type 2 diabetes. Diabetes Technol Ther. 2017;19:533–40. [PubMed]

58.

Evans M, Welsh Z, Ells S, Seibold A. The impact of flash glucose monitoring on glycemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies. Diabetes Ther. 2020;11:83–95. [DOI] [PubMed] [PMC]

59.

Gu W, Liu Y, Chen Y, Deng W, Ran X, Chen L, et al. Multicentre randomized controlled trial with sensor-augmented pump vs multiple daily injections in hospitalized patients with type 2 diabetes in China: time to reach target glucose. Diabetes Metab. 2017;43:359–63. [DOI] [PubMed]

60.

Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:19. [DOI] [PubMed] [PMC]

61.

Peters AL, Ahmann AJ, Battelino T, Evert A, Hirsch IB, Murad MH, et al. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:3922–37. [DOI] [PubMed]

62.

Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157:336–47. [DOI] [PubMed]

63.

Roze S, Duteil E, Smith-Palmer J, de Portu S, Valentine W, de Brouwer BF, et al. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands. J Med Econ. 2016;19:742–9. [DOI] [PubMed]

64.

Park C, Le QA. The effectiveness of continuous glucose monitoring in patients with type 2 diabetes: a systematic review of literature and meta-analysis. Diabetes Technol Ther. 2018;20:613–21. [DOI] [PubMed]

65.

Anjana RM, Pradeepa R, Deepa M, Jebarani S, Venkatesan U, Parvathi SJ, et al. Acceptability and utilization of newer technologies and effects on glycemic control in type 2 diabetes: lessons learned from lockdown. Diabetes Technol Ther. 2020;22:527–34. [DOI] [PubMed]

66.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9. [DOI] [PubMed]

67.

Grunberger G, Bailey T, Camacho PM, Einhorn D, Garber AJ, Handelsman Y, et al. Proceedings from the American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on glucose monitoring. Endocr Pract. 2015;21:522–33. [DOI] [PubMed]

68.

Bollyky JB, Bravata D, Yang J, Williamson M, Schneider J. Remote lifestyle coaching plus a connected glucose meter with certified diabetes educator support improves glucose and weight loss for people with type 2 diabetes. J Diabetes Res. 2018;2018:3961730. [DOI] [PubMed] [PMC]

69.

Öberg U, Isaksson U, Jutterström L, Orre CJ, Hörnsten Å. Perceptions of persons with type 2 diabetes treated in Swedish primary health care: qualitative study on using eHealth services for self-management support. JMIR Diabetes. 2018;3:e7. [DOI] [PubMed] [PMC]

70.

Ehrhardt NM, Chellappa M, Walker MS, Fonda SJ, Vigersky RA. The effect of real-time continuous glucose monitoring on glycemic control in patients with type 2 diabetes mellitus. J Diabetes Sci Technol. 2011;5:668–75. [DOI] [PubMed] [PMC]

71.

Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med. 2018;35:483–90. [DOI] [PubMed] [PMC]

72.

Reznik Y, Cohen O. Insulin pump for type 2 diabetes: use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes. Diabetes Care. 2013;36 suppl 2:S219–25. [DOI] [PubMed] [PMC]

73.

Reznik Y, Morera J, Rod A, Coffin C, Rousseau E, Lireux B, et al. Efficacy of continuous subcutaneous insulin infusion in type 2 diabetes mellitus: a survey on a cohort of 102 patients with prolonged follow-up. Diabetes Technol Ther. 2010;12:931–6. [DOI] [PubMed]

74.

Kravarusic J, Aleppo G. Diabetes technology use in adults with type 1 and type 2 diabetes. Endocrinol Metab Clin North Am. 2020;49:37–55. [DOI] [PubMed]